choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • CellCept

CellCept Newsletter
  • Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024) 24 Apr 2024 08:09 GMT

    … , a subcutaneous combination drug containing Perjeta. Specialty … (Product name: CellCept) for the treatment of systemic sclerosis … China by the National Medical Products Administration (NMPA) … treatment of endometriosis in January 2024. Chugai Pharmaceutical Co …

  • Despite price hikes, A continuing medicine crisis in regime areas 21 Feb 2024 19:40 GMT

    … types of stomach drugs and nerve treatments. Despite the … many medications remain unavailable amid news about several pharmaceutical factories … is almost impossible, especially Cellcept. Occasionally, the smuggled … that the prices of pills, capsules, and syrups …

  • CellCept side effects: What you should know 23 Jan 2024 15:59 GMT

    … Drug Administration (FDA) approves a drug, it tracks side effects of the medication … commonly reported in clinical trials of CellCept. Taking CellCept can increase your … serious infection during treatment with CellCept, talk with your doctor. They can …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month High at $19.68 12 Jan 2024 15:19 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 1-Year High at $19.61 29 Dec 2023 17:03 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Declines By 81.1% 14 Dec 2023 18:42 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High at $17.67 02 Dec 2023 13:17 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 52-Week High at $16.34 18 Nov 2023 15:22 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

  • Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 – present 18 Sep 2024 16:26 GMT

    Drug Sponsor Sponsor Medical Review Clinical … Golimumab - Simponi Janssen Biotech, Inc. Medical (PDF - 3.1 … mofetil - CellCept   Roche Palo Alto LLC Medical (PDF - … Boehringer Ingelheim Pharmaceuticals, Inc. Medical (PDF -11.9MB) Medical Addendum (PDF …

  • Chugai Pharmaceutical (OTCMKTS:CHGCY) Posts Quarterly Earnings Results 27 Oct 2023 15:35 GMT

    … sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … ; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, … ' ratings for Chugai Pharmaceutical and related companies with MarketBeat …

Satisfied with the content?

Continue to create your account.